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The multiple-dose pharmacokinetics of amoxicillin (AM [administered twice daily in a 25-mg/kg of body
weight intravenous dose]) in 17 preterm infants (11 males; gestational age, 29 6 1.9 weeks; birth weight, 1,175
6 278 g) were evaluated on day 3 of life. Blood samples were collected from an arterial catheter at 0, 0.5, 1, 2,
4, 8, and 12 h after the intravenous dose. A high-performance liquid chromatography method was used to
determine AM concentrations in serum. AM pharmacokinetics followed a one-compartment open model. The
glomerular filtration rates of all patients were simultaneously studied by means of the 24-h continuous inulin
infusion technique. The elimination half-life, apparent volume of distribution, and total body clearance of AM
(mean 6 standard deviation) were 6.7 6 1.7 h, 584 6 173 ml, and 62.4 6 23.3 ml/h, respectively. The mean (6
standard deviation) AM peak and trough levels were 53.66 9.1 and 16.06 4.9 mg/liter, respectively. All infants
had a serum trough level above 5 mg/liter. The total body clearance and apparent volume of distribution of AM
and the clearance of inulin increased significantly with increasing gestational age. The total body clearance of
AM (1.0 6 0.4 ml/min) and the clearance of inulin (1.0 6 0.3 ml/min) were similar. The total body clearance
of AM increased significantly with increasing clearance of inulin. We conclude that an AM dose of 25 mg/kg
every 12 h given to preterm infants in the first week of life with gestational ages of less than 32 weeks results
in serum levels well above the MIC for major microorganisms involved in neonatal infections.
Amoxicillin (AM), a penicillin derivative, is an antibiotic
frequently used for the treatment of infectious diseases in
newborn infants. It is active against common gram-positive
neonatal pathogens such as Listeria monocytogenes, Streptococ-
cus agalactiae, and Streptococcus faecalis and against gram-
negative bacilli, including non-b-lactamase-producing Hae-
mophilus influenzae and Escherichia coli. The combination of
AM with a broad-spectrum cephalosporin or an aminoglyco-
side is an effective empiric treatment of suspected neonatal
septicemia (21). Despite the widespread use of AM in neonatal
intensive care units, the pharmacokinetics of AM in preterm
infants have not been studied.
The currently recommended dosage for ampicillin in pre-
term infants of less than 4 weeks of life with a birth weight
below 1,200 g is 25 to 50 mg/kg of body weight every 12 h (12,
14, 15). Dosage recommendations for AM are extrapolated
from studies of ampicillin which did not stratify patients ac-
cording to gestational age (GA) or postnatal age (PA) (1, 3–5,
6, 11). However, the glomerular filtration rate (GFR) of pre-
term infants increases significantly with advancing GA and PA
(8, 19). This has a major effect on the pharmacokinetics of
antibiotics which are mainly excreted by glomerular filtration,
as has been demonstrated for the pharmacokinetics of cefta-
zidime (7). AM has a low level of serum protein binding
(617%) and is excreted primarily by glomerular filtration (18).
We hypothesized that the pharmacokinetic behavior of AM in
preterm infants in the first week of life would be influenced by
GA-dependent differences in GFR. We therefore investigated
the pharmacokinetics of AM (25 mg/kg/12 h) during the first
week of life in 17 infants with a GA below 32 weeks and
studied the effect of GA-dependent differences in GFR on the
kinetic parameters.
MATERIALS AND METHODS
Patients and study design. Seventeen preterm infants with GAs of less than 32
weeks, admitted to the neonatal intensive care unit with suspected or docu-
mented septicemia or invasive infection, were eligible for study. Subjects were
recruited by informed parental consent. The inclusion criteria were postnatal age
of 3 days, stability of hemodynamic function (diuresis, .1 ml/kg of body weight
per h; systolic and diastolic blood pressure above the third percentile adjusted for
GA), normal liver function, and no concurrent administration of nephrotoxic or
inotropic drugs. All patients had an indwelling arterial catheter. The partial
pressure of oxygen in arterial blood was kept at greater than 50 mm Hg (6,666
Pa), and the oxygen saturation was above 92%. Neonates assigned to receive
therapy were given AM (25 mg/kg intravenously [i.v.]) every 12 h and ceftazidime
(25 mg/kg i.v.) every 12 h. Patients with documented invasive bacterial infections
received at least 10 days of i.v. therapy. Patients with sterile cultures and without
a focus of infection received a total of 72 h of therapy. From each patient, the
following laboratory parameters were obtained: complete blood count with dif-
ferential and platelet count, blood and urine cultures, and arterial blood-gas
analysis.
Pharmacokinetics study. The pharmacokinetics of AM were studied on day 3
after birth. Blood samples were taken from indwelling arterial lines before
administration of an i.v. bolus injection (t5 0) and at 0.5, 1, 2, 4, 8, and 12 h after
the i.v. dose. Serum samples obtained after centrifugation in a microcentrifuge
(Merck-type Eppendorf 5414; 3,000 3 g for 1 min) were stored at 2708C.
Measurement of GFR. The GFR was measured by the continuous inulin
infusion technique on day 3 after birth (19). A 10% glucose–inulin solution
containing 25 g of inulin per liter was infused at a rate of 0.6 ml/kg/h, beginning
at time (t) zero of the pharmacokinetics study. After 24 h, the inulin clearance
(CLin) was calculated from the infusion rate (R), the inulin concentration in the
infusate (I), and the serum inulin concentration (Pin) by the equation CLin 5 (I
3 R)/Pin.
AM HPLC assay. Analysis of serum AM concentrations was performed ac-
cording to the method described by Haginaka and Wakai with minor modifica-
tions (9). HPLC-grade acetonitrile was purchased from Rathburn (Walkerburn,
Scotland). The other chemicals were purchased from Aldrich-Chemie (Stein-
heim, Germany). All chemicals applied were of the highest grade commercially
available. Chromatographic analysis was performed with a glass-prepacked col-
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umn (100 by 3 mm) containing ODS-2 Chromospher Spherisorb beads (5-mm-
diameter particle size; Chrompack, Middelburg, The Netherlands) combined
with a guard column. A Bio LC pump (model 410, Perkin-Elmer, Norwalk,
Conn.) was used to deliver the eluent: 15% (vol/vol) acetonitrile, 50 mM sodium
phosphate buffer, and 10 mM thiosulfate buffer (pH 4.6) at a flow rate of 0.8
ml/min. The separations were carried out at room temperature. The eluate was
monitored with a Perkin-Elmer LC-95 UV/visible spectrophotometer detector at
a wavelength of 328 nm.
To a 100-ml aliquot of the serum sample, 100 ml of 10 M urea solution was
added. Subsequently the mixture was ultrafiltrated with an Amicon MPS-1 mi-
cropartition system with Amicon YMT membranes (Amicon Corp., Lexington,
Mass.) by centrifugation at 1,500 3 g for 30 min at room temperature. To an
80-ml aliquot of the ultrafiltrate, 80 ml of 0.1 M borate buffer (pH 9.0) and 8 ml
of 0.2 M acetic anhydrate solution were added, and the mixture was allowed to
stand at room temperature for 3 min. Subsequently, 160 ml of 2 M triazole
reagent (pH 9.0) containing 1 mM mercury(II) chloride was added. The solution
was sealed in a screw-top vial and heated at 608C for 10 min. Subsequently, 20 ml
was transferred by an automatic sample injector (Perkin-Elmer) to the column.
A calibration curve was made by dissolving 4, 12, 25, 50, and 100 mg of AM per
ml in serum. These spiked standard samples were processed according to the
procedure mentioned above. A standard line of peak areas versus spiked AM
concentrations was determined. A linear calibration curve was obtained over a
range of 4 to 100 mg of AM per ml. Because the spiked samples of the calibration
curve underwent the same processing procedure as the clinical samples, the
clinical samples were directly converted by linear regression from the calibration
curve to actual AM concentrations per milliliter of serum. The lower limit of
detection of AM in serum was 1 mg/ml. The coefficients of interassay variation
determined at concentrations of 8.6 and 86 mg/ml were 7.9 and 3.4%, respec-
tively. The intraassay values were 2.1 and 4.7%, respectively. Recovery of 95% of
the derivatized AM, which had been incubated for 24 h at room temperature, was
established.
Pharmacokinetics analysis. Kinetics studies were performed on the third day
after birth. Visual inspection of individual model fits gave no indication that a
more complex (e.g., two-compartment) pharmacokinetics model was required.
Pharmacokinetics parameters were calculated with the multiple-dose formulae
described by Rowland and Tozer (16). The basic formula used was Ct 5 dose/
[V 3 (1 2 rN)]/[(1 2 r) 3 e2kt]. In this formula, Ct is the plasma concentration
of AM at given times t, V is the apparent volume of distribution, N is the dose
number, and r 5 e2kt, in which k is the elimination rate constant and t is the
dosing interval. Because doses were given twice daily, the AM concentration-
versus-time curve was assumed to be attributable to the 7th dose (and the trough
level at t 5 0 was assumed to be attributable to the 6th dose). The data were
weighted by 1/(predicted value)2. All calculations were carried out with the
nonlinear regression module of SPSS/PC1 V 4.0.1 (SPSS, Inc., Chicago, Ill.),
which uses a Levenberg-Marquardt algorithm.
RESULTS
Seventeen neonates, including 11 male and 6 female infants,
were enrolled in the study. The demographic and laboratory
parameters and the CLin data for these patients are shown in
Table 1. The pharmacokinetics parameters of AM are indi-
cated in Table 2. Figure 1 demonstrates the serum AM con-
centration (mean 6 standard deviation)-versus-time curve.
The mean peak and trough levels (6 standard deviation) were
53.6 6 9.1 and 16.0 6 4.9 mg/liter, respectively. All neonates
had serum trough levels above 5 mg/liter.
We examined the relationship between GA and CLin (as a
parameter of the GFR) in our patients. We demonstrated that
CLin increased significantly with increasing GA (r 5 0.84, P #
0.001). With increasing GA, total body clearance (CL) of AM
increased significantly (r 5 0.75, P 5 0.001) (Fig. 2). A similar
increase was detected for V (r 5 0.58, P 5 0.014). AM clear-
ance also increased significantly with weight (r 5 0.66, P ,
0.005). A similar increase was seen for V (r 5 0.78, P , 0.001).
After we normalized the parameters V and CL of AM for
weight, the previously significant correlations between GA and
V and between GA and CL disappeared (P 5 0.735 and P 5
0.283, respectively). CL of AM (1.0 6 0.4 ml/min) and CLin
(1.06 0.3 ml/min) were equal. We determined the presence of
FIG. 1. Serum drug concentration-versus-time profiles of AM (25 mg/kg of
body weight) in 17 preterm infants on day 3 after birth. Bars indicate standard
deviations.
FIG. 2. Linear regression analysis of GA (weeks) versus CL of AM (ml/h) in
17 preterm infants on day 3 after birth (r 5 0.75, P # 0.001, y 5 8.88x 2 181.2).
TABLE 1. Demographic and laboratory parameters of 17 patients
studied on day 3 after birth
Parameter Mean 6 SD
Age (wk) ............................................................................. 29 6 1 6/7
Sex (M/F)a .......................................................................... 11/6
Wt (g) .................................................................................. 1,1756 278
AGA/SGAb ......................................................................... 15/2
Culture positive .................................................................. 0
Hematocrit (%).................................................................. 446 7
Leukocytes (103/mm3) ....................................................... 15.6 6 12.6
Platelets (103/mm3)............................................................ 2156 112
Artificial ventilation (1/2)............................................... 10/7
aM, male; F, female.
b AGA, appropriate for GA; SGA, small for GA.
TABLE 2. Pharmacokinetics parameters of AM and CLin data
of 17 infants studied on day 3 after birth
Parameter Mean 6 SD
t1/2b (h) ....................................................................................... 6.7 6 1.7
CL (ml/min)............................................................................... 1.0 6 0.4
CL (ml/min/kg of body wt)...................................................... 1.16 0.2
V (ml) ......................................................................................... 5846 173
V (ml/kg).................................................................................... 671 6 117
CLin (ml/min) ............................................................................ 1.0 6 0.3
Trough level (mg/liter).............................................................16.06 4.9
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a regression between CLin and AM clearance. We found that
AM clearance was equal to (47.1 3 inulin clearance) 1 28.
Calculations showed no significant relationships between GA
and CLin versus the elimination half-life (t1/2b) of AM (Table
3). In addition, the elimination rate constant and CLin were
fitted and no relationship was detected.
DISCUSSION
During the previous decade, it became apparent that the
pharmacokinetics of a large variety of drugs in preterm infants
are significantly different from those in full-term children.
Clearance rates are usually much slower in the preterm infant,
mainly because of immaturity of renal function of hepatic drug
metabolism. Dosage recommendations for the use of AM in
preterm neonates have been extrapolated from data about
ampicillin obtained for infants and adults (10, 17). We ques-
tioned the validity of these recommendations and studied the
pharmacokinetics of AM in preterm infants with GAs of less
than 32 weeks on day 3 of life by using the lowest recom-
mended dose (25 mg/kg/12 h i.v.).
Our results indicate that administration of this dose results
in high serum drug levels during the complete dosing interval.
The MIC of AM for AM-susceptible microorganisms, includ-
ing non-b-lactamase-producing H. influenzae and E. coli, does
not exceed 5 mg/liter (20). Taking this level as a reference,
serum AM levels are sufficiently high. The prolonged t1/2b of
AM (6.70 6 1.67 h) and the high serum drug trough levels
(16.0 6 4.9 mg/liter) suggest that the dosing interval may even
be extended to 618 h. A study of 10 infants with a mean age
of 10 months showed a substantially lower serum drug half-life
(mean t1/2b 5 1.22 h) (17). A serum drug half-life of 1.1 to 1.3
h after administration of different i.v. doses of AM was also
found in seven healthy adults (10). AM is predominantly ex-
creted in the urine in unaltered form.
It has been shown that CL of penicillin in the newborn is not
significantly greater than creatinine clearance (13). These find-
ings suggest that glomerular filtration, rather than tubular se-
cretion, is primarily responsible for most of the renal elimina-
tion of penicillin in neonates. CL increases with age and
surpasses creatinine clearance, which probably reflects the de-
velopment of renal function (both filtration and secretion)
throughout the neonatal period. Our results showed that the
GFR (1.0 6 0.3 ml/min) and the CL (1.0 6 0.4 ml/min) of AM
were equal. We therefore assume that AM, like penicillin, is
almost completely cleared by glomerular filtration in preterm
infants with GAs of less than 32 weeks during the first days of
life. This is also in agreement with previous studies of penicil-
lins in older neonates and infants (14, 15).
The GFR increased in our patients with advancing GA.
These data are in agreement with those from other studies in
which a positive relationship between the GA and the GFR
was detected (8, 19). We also found a positive correlation
between the GA and the CL of AM (r 5 0.75, P 5 0.001). This
was not surprising in view of the relationship between GA and
GFR and GFR and AM clearance.
The V of many drugs is altered in infants during the first
month of life because of the difference in body composition.
Approximately 75% of total body weight in the newborn is
water. Hence, drugs that are water soluble and that are dis-
tributed in extracellular water (e.g., aminoglycosides or peni-
cillins) have an increased V per kilogram of body weight (2).
Our data show that the V of AM, as expected, increased with
body weight (r 5 0.78, P , 0.001).
A significant relationship between the t1/2b and the GA
could not be demonstrated in our patients. One must take into
account that not only the clearance but also V affects the t1/2b
of AM. With increasing GA, CL increased, which would be
expected to lead to a decrease in t1/2b. The V also increased,
which would be expected to result in an increase in t1/2b. The
interaction between these two developmental mechanisms may
explain the absence of a significant relationship between GA
and the t1/2b of AM.
The present data indicate that preterm infants in the first
week of life with GAs of less than 32 weeks should receive a
maximum AM dosage of 25 mg/kg/12 h. This is only one-half or
less of the dosage given to more mature infants but will result
in serum drug levels well above the MIC for the major micro-
organisms involved in neonatal infections. Further studies are
necessary to elucidate if higher dosage recommendations are
necessary in preterm infants with PAs of between 1 and 4
weeks.
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